Mr. Rob Hill reports

EMERALD HEALTH THERAPEUTICS' LICENSED ENDO PRODUCT LINE GAINS BOOST WITH ENTRY INTO WHOLE FOODS MARKET STORES ACROSS US

Emerald Health Therapeutics Inc.'s joint venture partner, San Diego-based Emerald Health Bioceuticals (EHB), has launched its award-winning Endo products in Whole Foods Markets across the United States, highlighting the unique positioning and opportunity for this product line when it is launched in Canada in 2019. The joint venture, called Emerald Health Naturals (EHN), secured Canadian distribution rights for this product line that was developed to support the body's endocannabinoid system (ECS), but which does not contain cannabis. Canadian retailers have not been announced.

In December, 2018, EHT received natural product numbers (NPNs) from Health Canada to sell Endo in Canada. EHN is owned 51 per cent by Emerald and 49 per cent by EHB.

"For the Endo products to be embraced by retailers with such high standards of retail excellence and broad reach like Whole Foods Market in the U.S. is an important milestone for this unique natural health supplement line," said Gaetano Morello, ND, chief executive officer of Emerald Health Naturals. "A non-cannabis product line capable of nurturing the endocannabinoid system is a unique product category -- and it is one that is garnering significant attention in the U.S. We aim to similarly build strong distribution channels with top retailers in Canada in 2019."

"With 60 per cent of cannabis users also being users of natural health products, we have a two-pronged opportunity in Canada to build a stand-alone market for the Endo product line for cannabis non-users as well as achieve Emerald brand recognition among cannabis users in channels unable to carry cannabis products," said Avtar Dhillon, president and executive chairman, Emerald Health Therapeutics. "Natural health product stores, pharmacies and even grocery stores may all be potential outlets for the Endo product line. We look forward to offering the proprietary Endo products to Canadian consumers this year."

Endo nutritional supplements feature PhytoCann-Complex, a proprietary formulation consisting of non-cannabis, non-psychoactive, plant-based bioactive compounds that support the body's endocannabinoid system. The role of the ECS as the body's innate balancing mechanism is key to the regulation of everything from appetite, energy, metabolism, fertility and immunity to sleep, mood, pain perception and memory. The Endo product line includes Endo Brain, Endo Sleep, Endo Calm, Endo Bliss and Endo Inflame, and they are intended to naturally address the body's response to conditions such as stress, anxiety, restless sleep and pain, and foster overall health and wellness.

Over the last year, EHB has secured multiple distribution and sales channels for the Endo product line in the United States and internationally, ranging from small independent natural health product retailers to nationwide grocery store chains like Whole Foods Market, as well as Amazon.

About the Endo product line (1):

• Endo Brain: Naturally support mental acuity and cognition by nurturing and nourishing your endocannabinoid system.
• Endo Sleep: Enjoy restful and rejuvenating sleep by naturally supporting your endocannabinoid system, optimal health and vitality.
• Endo Calm: Naturally address your body's response to stress and anxiety by supporting your endocannabinoid system and optimal health and vitality.
• Endo Bliss: Naturally support a positive outlook and resistance to daily pressures by nurturing and nourishing your endocannabinoid system.
• Endo Inflame: Naturally promote your body's healthy response to pain and inflammation by supporting your endocannabinoid system for optimal health and vitality.

(1) The statements made herein have not been evaluated by Health Canada or the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About Emerald Health Therapeutics Inc.

Emerald Health Therapeutics is a Canadian licensed producer of cannabis. Its 50-per-cent-owned Pure Sunfarms joint venture in British Columbia is completing the conversion of its 1.1-million-square-foot (25-acre) greenhouse for cannabis cultivation in the Lower Mainland and its Verdelite operation in Quebec is completing the build out of its 75,000-square-foot indoor cultivation facility. Commercial production is expanding in both facilities. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1,000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD).

We seek Safe Harbor.